Kodiak Sciences

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein for the treatment of retinal inflammatory diseases. We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients for multifactorial diseases. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.